Medication-Assisted Treatment - Prescription Drug and Opioid Addiction(MAT-PDOA)

FUNDER: Substance Abuse and Mental Health Services Administration (SAMHSA) – Center for Substance Abuse Treatment

Link to Funding Opportunity: https://www.samhsa.gov/sites/default/files/grants/pdf/fy-2023-mat-pdoa-nofo.pdf

DUE DATE > March 7, 2023



PURPOSE

The purpose of this program is to provide resources to help expand and enhance access to Medications for Opioid Use Disorder (MOUD). It is expected that this program will help to 1) increase access to MOUD for individuals with Opioid Use Disorder (OUD), including individuals from diverse racial, ethnic, sexual and gender minorities communities; and 2) decrease illicit opioid use and prescription opioid misuse.

Award recipients will be expected to provide FDA-approved MOUD in an ongoing manner. MOUD includes methadone, buprenorphine/naloxone combination and single formulation products, in sublingual tablets or film or extended release, long-acting injections, and extended-release injectable naltrexone. MOUD is to be provided in combination with comprehensive psychosocial services, including counseling, behavioral therapies, recovery support services (RSS), and other clinically appropriate services.



ELIGIBILITY

Eligible Applicants are:

- States, political subdivisions of States, Indian tribes, or tribal organizations (as such terms are defined in section 4 of the Indian Self-Determination and Education Assistance Act)
- Health facilities, or programs operated by or in accordance with a contract or grant with the Indian Health Services
- Public or non-profit private entities.



FUNDING LEVEL

- Estimated Number of Awards: 24 (up to 13 for tribal organizations)
- Award Amount: \$750,000 per year
- Length of Project Period: 5 years
- No Match or Cost Sharing Required



Award recipients must use SAMHSA's funds to support direct services primarily. This includes the following activities by the 4th month of funding:

- Provide MOUD with at least one of the FDA-approved medications (e.g., methadone, buprenorphine/naloxone products/buprenorphine products including sublingual tablets/film, and extended release, long-acting injectable buprenorphine formulations and injectable naltrexone) in combination with comprehensive psychosocial services, counseling, behavioral therapies, RSS, and other clinically appropriate services.
- Conduct an appropriate clinical assessment to establish the diagnosis and severity level of OUD based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition(DSM-5) diagnostic criteria and with information necessary to identify a recommended level of care and develop an individualized treatment and recovery planusing a shared decision-making approach.

- Provide evidence-based and population appropriate treatment services to meet the unique needs of diverse populations at risk. Treatment services must include the use of FDA-approved medications in the treatment of opioid and/or alcohol use disorder and medication management (if available in the geographic area served), outpatient, day treatment (including outreach-based services), intensive outpatient, or residential programs.
- Check the state, county, or local Prescription Drug Monitoring Program (PDMP), where available, for each new patient admission in compliance with any relevant state rules or regulations.
- Conduct screening and assessment for co-occurring substance use and mental disorders and develop a plan to either deliver or coordinate any services determined to be necessary for the individual patient to achieve and sustain recovery.



- Develop and implement outreach and engagement strategies to increase access to MOUD and related services for diverse populations with OUD and monitor uneven or inequitable access to different medications/MOUD (e.g., buprenorphine, methadone) across these populations.
- Ensure all applicable practitioners working on the project obtain any federal, state, or other required training on substance use disorders and/or opioid use disorder for the prescribing of buprenorphine.
- Use telehealth services, or other innovative interventions, to reach, engage, and retain patients in treatment.



- Build funding mechanisms and service delivery models with rural and resource-limited counties and municipalities, organizations such as health plans, integrated health systems, universities, hospitals, including emergency departments, clinics, community-based organizations, in particular those serving diverse sexual orientation, gender identity, and racial and ethnic minority populations, law enforcement, community recovery organizations, faith-based organizations, and/or other local community and culture-specific coalitions in order to provide a robust suite of treatment and RSS that effectively identify, engage, and retain individuals in OUD treatment and facilitate long-term recovery.
- This also includes Opioid Treatment Programs (OTPs) such that access to OUD treatment with methadone is available for patients of service providers that may not themselves be able to offer this medication.



- To improve access to and retention in MOUD and facilitate long-term recovery, provide or develop formal partnerships to provide RSS, including peer recovery support services, and with culturally-specific organizations.
- Develop and provide harm reduction services on site, either singularly or in collaboration with a community-based harm reduction organization, to include overdose prevention education and naloxone distribution, education on the provision of fentanyl test strips, syringe services, and/or other harm reduction services.



ADDITIONAL CONSIDERATIONS

Program Infrastructure Development required activity (maximum 15 percent of grant funds):

- Developing Partnerships
- Training the workforce
- Policy Development

NOTE: This funding may also be used to establish MOBILE MAT UNITS!



STRATEGY

Based on our experience, these are our recommendations.

- We suggest that you carefully review the funding announcement and solidify any needed MOUs with community collaborators
- Review current client MAT data to determine if disparities exist among adults with respect to access or outcomes.
- Review your evidence-based practices for effectiveness with the population of focus, including racial and cultural considerations.



NEXT STEPS

Helping you build toward your tomorrow.

SAE is available to collaborate with you to write the proposal, provide a review of your proposal, or to provide technical assistance in developing your program plan.

- Immediately validate that you have accounts in the System for Awards Management (SAM), Grants.gov, and era Commons.
- Create a table to assess your current level of implementation for each of the required activities and what you plan to expand or enhance with grant funding for each year of the funding period.
- Use this table to begin developing your staffing plan and program budget.
- Contact SAE for a free consultation to discuss this funding opportunity and your ideas for your proposal.



WE WELCOME THE OPPORTUNITY TO ASSIST YOU & YOUR TEAM! Reach out today to schedule a no-cost consultation.



CONTACT US

SAE Behavioral Health Consulting

WEBSITE www.saebhc.com

EMAIL info@saebhc.com

PHONE (212) 684-4480